JP2020516296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516296A5 JP2020516296A5 JP2019555936A JP2019555936A JP2020516296A5 JP 2020516296 A5 JP2020516296 A5 JP 2020516296A5 JP 2019555936 A JP2019555936 A JP 2019555936A JP 2019555936 A JP2019555936 A JP 2019555936A JP 2020516296 A5 JP2020516296 A5 JP 2020516296A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- nos
- salt
- compound
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims description 246
- 150000001875 compounds Chemical class 0.000 claims description 236
- 108020004459 Small interfering RNA Proteins 0.000 claims description 76
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 40
- 125000005647 linker group Chemical group 0.000 claims description 38
- 229910052739 hydrogen Inorganic materials 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 36
- 125000001475 halogen functional group Chemical group 0.000 claims description 35
- 125000003545 alkoxy group Chemical group 0.000 claims description 28
- 125000003118 aryl group Chemical group 0.000 claims description 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 125000001072 heteroaryl group Chemical group 0.000 claims description 23
- 239000007787 solid Substances 0.000 claims description 23
- 125000000304 alkynyl group Chemical group 0.000 claims description 18
- 230000008685 targeting Effects 0.000 claims description 15
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 claims description 14
- 239000003446 ligand Substances 0.000 claims description 14
- 150000007523 nucleic acids Chemical group 0.000 claims description 13
- 125000004429 atom Chemical group 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 10
- 150000001720 carbohydrates Chemical class 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- -1 salts compound Chemical class 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 3
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 238000013160 medical therapy Methods 0.000 claims description 2
- 230000000069 prophylactic effect Effects 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims 4
- 238000010168 coupling process Methods 0.000 claims 4
- 238000005859 coupling reaction Methods 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 37
- 125000004432 carbon atom Chemical group C* 0.000 description 26
- 0 CC(C)(C)N(CCC1)C1C(CO*=C)O Chemical compound CC(C)(C)N(CCC1)C1C(CO*=C)O 0.000 description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 16
- 150000002431 hydrogen Chemical class 0.000 description 16
- 239000012071 phase Substances 0.000 description 16
- 229920006395 saturated elastomer Polymers 0.000 description 15
- 229930195734 saturated hydrocarbon Natural products 0.000 description 15
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 14
- 125000004043 oxo group Chemical group O=* 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 14
- 150000001345 alkine derivatives Chemical class 0.000 description 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 11
- 125000004104 aryloxy group Chemical group 0.000 description 11
- 150000001540 azides Chemical class 0.000 description 11
- 125000004093 cyano group Chemical group *C#N 0.000 description 11
- 125000005553 heteroaryloxy group Chemical group 0.000 description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 235000000346 sugar Nutrition 0.000 description 9
- 125000001188 haloalkyl group Chemical group 0.000 description 8
- 125000004414 alkyl thio group Chemical group 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 6
- 125000004438 haloalkoxy group Chemical group 0.000 description 5
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 4
- 125000004423 acyloxy group Chemical group 0.000 description 4
- 125000001589 carboacyl group Chemical group 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 150000008574 D-amino acids Chemical class 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 3
- 208000009594 Animal Hepatitis Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 208000029433 Herpesviridae infectious disease Diseases 0.000 description 2
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 description 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ADYGKTWSELPLSQ-UHFFFAOYSA-N CC(C)(CCO)OC(C(C1O)NC(C)=O)OC(CO)C1O Chemical compound CC(C)(CCO)OC(C(C1O)NC(C)=O)OC(CO)C1O ADYGKTWSELPLSQ-UHFFFAOYSA-N 0.000 description 1
- QQGNLKJAIVSNCO-UHFFFAOYSA-N CCCCNC=O Chemical compound CCCCNC=O QQGNLKJAIVSNCO-UHFFFAOYSA-N 0.000 description 1
- NZHMROSYTLLOCR-GFMAATOTSA-N CCCOC([C@@H]([C@H]1O)NC(C)=O)OC[C@@H]1O Chemical compound CCCOC([C@@H]([C@H]1O)NC(C)=O)OC[C@@H]1O NZHMROSYTLLOCR-GFMAATOTSA-N 0.000 description 1
- UJUOHBCTKYTJEZ-UHFFFAOYSA-N CCN(C)NC(CC[O](C)C)(CC1)CC1O Chemical compound CCN(C)NC(CC[O](C)C)(CC1)CC1O UJUOHBCTKYTJEZ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 125000005103 alkyl silyl group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000011421 subcutaneous treatment Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022176285A JP7564173B2 (ja) | 2017-04-11 | 2022-11-02 | 標的化組成物 |
| JP2024166900A JP2024174053A (ja) | 2017-04-11 | 2024-09-26 | 標的化組成物 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762484247P | 2017-04-11 | 2017-04-11 | |
| US62/484,247 | 2017-04-11 | ||
| US201762525071P | 2017-06-26 | 2017-06-26 | |
| US62/525,071 | 2017-06-26 | ||
| PCT/US2018/026918 WO2018191278A2 (en) | 2017-04-11 | 2018-04-10 | Targeted compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022176285A Division JP7564173B2 (ja) | 2017-04-11 | 2022-11-02 | 標的化組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020516296A JP2020516296A (ja) | 2020-06-11 |
| JP2020516296A5 true JP2020516296A5 (enExample) | 2021-05-27 |
Family
ID=62063656
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019555936A Pending JP2020516296A (ja) | 2017-04-11 | 2018-04-10 | 標的化組成物 |
| JP2022176285A Active JP7564173B2 (ja) | 2017-04-11 | 2022-11-02 | 標的化組成物 |
| JP2024166900A Pending JP2024174053A (ja) | 2017-04-11 | 2024-09-26 | 標的化組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022176285A Active JP7564173B2 (ja) | 2017-04-11 | 2022-11-02 | 標的化組成物 |
| JP2024166900A Pending JP2024174053A (ja) | 2017-04-11 | 2024-09-26 | 標的化組成物 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11427823B2 (enExample) |
| EP (2) | EP3950004A1 (enExample) |
| JP (3) | JP2020516296A (enExample) |
| KR (3) | KR20250145702A (enExample) |
| CN (2) | CN118460536A (enExample) |
| AU (2) | AU2018250553B2 (enExample) |
| BR (1) | BR112019021359A2 (enExample) |
| CA (1) | CA3059426A1 (enExample) |
| MA (1) | MA52546A (enExample) |
| MX (3) | MX2019012280A (enExample) |
| NZ (1) | NZ757927A (enExample) |
| PH (1) | PH12019502333A1 (enExample) |
| SG (1) | SG11201909433XA (enExample) |
| TW (2) | TWI805577B (enExample) |
| WO (1) | WO2018191278A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA45478A (fr) | 2016-04-11 | 2019-02-20 | Arbutus Biopharma Corp | Compositions de conjugués d'acides nucléiques ciblés |
| KR20250145702A (ko) | 2017-04-11 | 2025-10-13 | 아뷰터스 바이오파마 코포레이션 | 표적화 조성물 |
| US11414665B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| WO2019105418A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
| KR102834361B1 (ko) | 2017-12-01 | 2025-07-17 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 핵산, 이를 포함하는 조성물과 컨쥬게이트, 및 그의 제조 방법과 용도 |
| JP7365052B2 (ja) | 2017-12-01 | 2023-10-19 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| US11414661B2 (en) | 2017-12-01 | 2022-08-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| CA3087106A1 (en) | 2017-12-29 | 2019-07-04 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
| JP2021533800A (ja) | 2018-08-21 | 2021-12-09 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd. | 核酸、当該核酸を含む薬物組成物及び複合体ならびにその使用 |
| CN111655297A (zh) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
| WO2020093053A1 (en) * | 2018-11-02 | 2020-05-07 | Arbutus Biopharma Corporation | Bivalent targeted conjugates |
| US20220031847A1 (en) * | 2018-11-02 | 2022-02-03 | Genevant Sciences Gmbh | Therapeutic methods |
| EP3941921A4 (en) * | 2019-03-20 | 2023-05-03 | Arbutus Biopharma Corporation | Therapeutic methods for treating hepatitis b |
| EP3974530A4 (en) * | 2019-05-22 | 2023-07-12 | Suzhou Ribo Life Science Co., Ltd. | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, METHOD FOR PREPARATION AND USE |
| US20220305107A1 (en) | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi |
| WO2021113820A1 (en) * | 2019-12-06 | 2021-06-10 | Genevant Sciences Gmbh | Conjugates and methods for treating liver fibrosis |
| EP4077473A4 (en) | 2019-12-20 | 2024-05-01 | Arbutus Biopharma Corporation | SYNTHETIC PROCESSES AND INTERMEDIATE PRODUCTS |
| JP2023548295A (ja) * | 2020-11-06 | 2023-11-16 | アルブータス・バイオファーマー・コーポレイション | 修飾されたｓｉＲＮＡを含む標的化コンジュゲート |
| CN114853829A (zh) * | 2021-02-05 | 2022-08-05 | 上海拓界生物医药科技有限公司 | 一种核酸配体、其缀合物、制备方法及用途 |
| CN118355121A (zh) * | 2021-12-16 | 2024-07-16 | 上海拓界生物医药科技有限公司 | 一种dsRNA、其制备方法及应用 |
| KR20240136985A (ko) * | 2022-01-20 | 2024-09-19 | 청두 신정허 파마슈티컬 테크놀로지 컴퍼니 리미티드 | 표적화 리간드 및 이의 용도 |
| CN116917477B (zh) * | 2022-01-30 | 2024-04-09 | 大睿生物医药科技(上海)有限公司 | 含有n-乙酰半乳糖胺的靶向配体 |
| WO2023178144A2 (en) | 2022-03-16 | 2023-09-21 | Empirico Inc. | Galnac compositions for improving sirna bioavailability |
| WO2024255761A1 (zh) * | 2023-06-12 | 2024-12-19 | 大睿生物 | 包含糖的寡核苷酸递送配体 |
| WO2025007907A1 (zh) * | 2023-07-04 | 2025-01-09 | 大睿生物 | 包含肽的寡核苷酸递送配体 |
| WO2025007274A1 (zh) * | 2023-07-04 | 2025-01-09 | 成都先导药物开发股份有限公司 | 一种缀合物及其中间体化合物和用途 |
| WO2025242321A1 (en) | 2024-05-24 | 2025-11-27 | Glaxosmithkline Intellectual Property (No.3) Limited | Novel use |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US6303120B1 (en) | 1994-03-15 | 2001-10-16 | Memorial Sloan-Kettering Institute For Cancer Research | Synthesis of glycoconjugates of the lewis y epitope and uses thereof |
| US5708163A (en) | 1994-03-15 | 1998-01-13 | Sloan-Kettering Institute Of Cancer Research | Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof |
| US5885613A (en) | 1994-09-30 | 1999-03-23 | The University Of British Columbia | Bilayer stabilizing components and their use in forming programmable fusogenic liposomes |
| EP1096921B1 (en) | 1998-07-20 | 2003-04-16 | Protiva Biotherapeutics Inc. | Liposomal encapsulated nucleic acid-complexes |
| US7833992B2 (en) | 2001-05-18 | 2010-11-16 | Merck Sharpe & Dohme | Conjugates and compositions for cellular delivery |
| WO2003070918A2 (en) * | 2002-02-20 | 2003-08-28 | Ribozyme Pharmaceuticals, Incorporated | Rna interference by modified short interfering nucleic acid |
| US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US8258288B2 (en) | 2002-02-20 | 2012-09-04 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA) |
| US7901708B2 (en) | 2002-06-28 | 2011-03-08 | Protiva Biotherapeutics, Inc. | Liposomal apparatus and manufacturing methods |
| US20080207539A1 (en) * | 2003-09-01 | 2008-08-28 | Patrick Arbuthnot | Self-Processing Rna Expression Cassette |
| WO2005026165A1 (en) | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Quinolone antibacterial agents |
| JP5639338B2 (ja) | 2005-07-27 | 2014-12-10 | プロチバ バイオセラピューティクス インコーポレイティッド | リポソームの製造システムおよび製造方法 |
| CA2688240A1 (en) | 2007-05-24 | 2008-12-04 | The United States Government As Represented By The Department Of Veterans Affairs | Intranuclear protein transduction through a nucleoside salvage pathway |
| EP3705125B1 (en) | 2007-12-04 | 2023-07-05 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| AU2008340354B2 (en) | 2007-12-04 | 2014-04-17 | Alnylam Pharmaceuticals, Inc. | Folate-iRNA conjugates |
| US8541388B2 (en) | 2008-05-22 | 2013-09-24 | Isis Pharmaceuticals, Inc. | Methods for modulating expression of RBP4 |
| CN101603042B (zh) * | 2008-06-13 | 2013-05-01 | 厦门大学 | 可用于乙型肝炎病毒感染治疗的rna干扰靶点 |
| WO2010006282A2 (en) | 2008-07-10 | 2010-01-14 | Serina Therapeutics, Inc. | Polyoxazolines with inert terminating groups, polyoxazolines prepared from protected initiating groups and related compounds |
| JP5723378B2 (ja) | 2009-11-03 | 2015-05-27 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | トランスサイレチン（ｔｔｒ）を阻害する脂質製剤化組成物及び方法 |
| ES2562817T3 (es) | 2010-02-24 | 2016-03-08 | Arrowhead Research Corporation | Composiciones para el suministro dirigido de ARNip |
| KR20130132475A (ko) | 2010-12-17 | 2013-12-04 | 애로우헤드 리서치 코오포레이션 | ｓｉＲＮＡ의 갈락토오스 클러스터-약동학적 조절제 표적 물질 |
| EP2751270B1 (en) | 2011-08-29 | 2018-08-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| MY167390A (en) | 2011-11-18 | 2018-08-16 | Alnylam Pharmaceuticals Inc | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
| KR20250133484A (ko) | 2011-11-18 | 2025-09-05 | 알닐람 파마슈티칼스 인코포레이티드 | 변형된 ＲＮＡｉ 제제 |
| SG11201503821YA (en) | 2012-11-15 | 2015-06-29 | Roche Innovation Ct Copenhagen As | Oligonucleotide conjugates |
| KR102482890B1 (ko) | 2013-05-01 | 2022-12-30 | 아이오니스 파마수티컬즈, 인코포레이티드 | 아포지질단백질 (a) 발현을 조절하는 조성물 및 방법 |
| AU2014284152B2 (en) | 2013-06-21 | 2020-01-23 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of target nucleic acids |
| DK3013959T3 (da) | 2013-06-27 | 2020-02-17 | Roche Innovation Ct Copenhagen As | Antisense-oligomerer og konjugater målrettet pcsk9 |
| AR097738A1 (es) | 2013-09-23 | 2016-04-13 | Alnylam Pharmaceuticals Inc | Métodos para tratar o prevenir enfermedades asociadas con la transtiretina (ttr) |
| CN106232125B (zh) | 2014-05-01 | 2020-10-16 | Ionis制药公司 | 用于调节pkk表达的组合物和方法 |
| JOP20200115A1 (ar) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات)) |
| KR20170068469A (ko) | 2014-10-10 | 2017-06-19 | 에프. 호프만-라 로슈 아게 | ＧａｌＮＡｃ 포스포라미다이트, 그의 핵산 컨쥬게이트 및 그의 용도 |
| JOP20200092A1 (ar) * | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
| TWI806034B (zh) | 2015-05-06 | 2023-06-21 | 美商阿尼拉製藥公司 | 第十二因子（哈格曼因子）（Ｆ１２）、激肽釋放素Ｂ、血漿（夫列契因子）１（ＫＬＫＢ１）及激肽原１（ＫＮＧ１）ｉＲＮＡ組成物及其使用方法 |
| MA45478A (fr) | 2016-04-11 | 2019-02-20 | Arbutus Biopharma Corp | Compositions de conjugués d'acides nucléiques ciblés |
| KR20250145702A (ko) | 2017-04-11 | 2025-10-13 | 아뷰터스 바이오파마 코포레이션 | 표적화 조성물 |
| SG11201909572QA (en) * | 2017-04-18 | 2019-11-28 | Alnylam Pharmaceuticals Inc | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection |
| EP3941921A4 (en) | 2019-03-20 | 2023-05-03 | Arbutus Biopharma Corporation | Therapeutic methods for treating hepatitis b |
| US20220305107A1 (en) * | 2019-06-18 | 2022-09-29 | Janssen Sciences Ireland Unlimited Company | COMBINATION OF HEPATITIS B VIRUS (HBV) VACCINES AND HBV-TARGETING RNAi |
-
2018
- 2018-04-10 KR KR1020257032179A patent/KR20250145702A/ko active Pending
- 2018-04-10 BR BR112019021359-7A patent/BR112019021359A2/pt unknown
- 2018-04-10 JP JP2019555936A patent/JP2020516296A/ja active Pending
- 2018-04-10 KR KR1020247011466A patent/KR102866327B1/ko active Active
- 2018-04-10 CN CN202410526906.0A patent/CN118460536A/zh active Pending
- 2018-04-10 KR KR1020197033270A patent/KR102656438B1/ko active Active
- 2018-04-10 WO PCT/US2018/026918 patent/WO2018191278A2/en not_active Ceased
- 2018-04-10 MX MX2019012280A patent/MX2019012280A/es unknown
- 2018-04-10 NZ NZ757927A patent/NZ757927A/en unknown
- 2018-04-10 EP EP21152689.2A patent/EP3950004A1/en active Pending
- 2018-04-10 SG SG11201909433X patent/SG11201909433XA/en unknown
- 2018-04-10 EP EP18720744.4A patent/EP3610017A2/en active Pending
- 2018-04-10 CN CN201880038780.5A patent/CN110741087B/zh active Active
- 2018-04-10 US US16/603,771 patent/US11427823B2/en active Active
- 2018-04-10 CA CA3059426A patent/CA3059426A1/en active Pending
- 2018-04-10 AU AU2018250553A patent/AU2018250553B2/en active Active
- 2018-04-10 MA MA052546A patent/MA52546A/fr unknown
- 2018-04-11 TW TW107112376A patent/TWI805577B/zh active
- 2018-04-11 TW TW112118993A patent/TW202413641A/zh unknown
-
2019
- 2019-10-11 MX MX2024004432A patent/MX2024004432A/es unknown
- 2019-10-11 PH PH12019502333A patent/PH12019502333A1/en unknown
- 2019-10-11 MX MX2024004433A patent/MX2024004433A/es unknown
-
2022
- 2022-06-30 US US17/854,575 patent/US12043833B2/en active Active
- 2022-11-02 JP JP2022176285A patent/JP7564173B2/ja active Active
-
2024
- 2024-06-05 US US18/734,444 patent/US20250179496A1/en active Pending
- 2024-09-26 JP JP2024166900A patent/JP2024174053A/ja active Pending
-
2025
- 2025-02-18 AU AU2025201146A patent/AU2025201146A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516296A5 (enExample) | ||
| Chakraborty et al. | Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy | |
| JP5539460B2 (ja) | 癌免疫治療のための組成物および方法 | |
| AU2019226586B2 (en) | Compounds including a mutant KRAS sequence and a lipid and uses thereof | |
| JP2018021047A (ja) | 癌免疫療法 | |
| DE102006035618A1 (de) | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz | |
| JP2019504002A5 (enExample) | ||
| WO2007095976A2 (de) | Adjuvanz in form einer lipid-modifizierten nukleinsäure | |
| BR112020008546A2 (pt) | construtos de oligonucleotídeo e usos dos mesmos | |
| US20250171507A1 (en) | Cpg amphiphiles and uses thereof | |
| JP6583864B2 (ja) | 免疫賦活活性を有する核酸誘導体 | |
| TWI861015B (zh) | 包含抗原肽-佐劑核苷酸結合物之免疫誘導劑及包含其之醫藥組成物 | |
| JP6017766B2 (ja) | 新規な金属サレン錯体化合物の抗がん剤 | |
| JP2020518649A5 (enExample) | ||
| EP4410305A1 (en) | Anticancer vaccine composition comprising hsp90 antigenic peptide and use thereof | |
| KR102138415B1 (ko) | 신규 peg 유도체 | |
| ES2786025T3 (es) | Productos conjugados de proteína-polímero | |
| Liu et al. | Albumin-binding toll-like receptor 7 agonist nanocomplexes elicit antitumor immunity for cancer immunotherapy | |
| KR20250087641A (ko) | 생물 활성 성분을 전달하기 위한 아미노 지질 화합물 및 지질 나노입자 | |
| KR20250151446A (ko) | 종양-관련 대식세포를 표적화하기 위한 조성물 및 방법 | |
| HK40043266A (en) | Cpg amphiphiles and uses thereof | |
| WO2025183164A1 (ja) | エピジェネティクス関連タンパク質分解技術 | |
| EP4125862A1 (en) | Cancer therapy with microbubbles |